| | Treatment conditions | Stem cell type | The effect compared to normoxia (methods of analysis) | Ref | | An agent/concentration | Time |
| | DFO/3 μM | Treatment for 14 d | hBM-MSC | Osteogenic (Alizarin Red staining, 14 d) and adipogenic (Oil Red staining, 14 d) potential decreased | [61] | | DFO/15 μM | Treatment for 7 d | hBM-MSC | ALP increased (WB, 7 d) | [120] | | DFO/15 μM | Treatment for 21 d | hBM-MSC | Osteogenic potential increased (Alizarin Red staining, 21 d), ALP, RUNX2, and OC upregulated (qRT-PCR), osteogenesis through β-catenin signaling increased (WB) | [120] | | DFO/50 μM | Treatment for 21 d | hBM-MSC | Chondrogenesis (Alcian Blue, 21 d) and SOX9 expression (RT-PCR, 7 d) slightly increased | [124] | | DFO/120 μM | Treatment for 8 d | mBM-MSC | Adipogenic potential preserved (Sudan Black staining, 8 d), Oct4 expression maintained (qRT-PCR) | [123] | | DFO/120 μM | Treatment for 21 d | hUC-MSC | Osteogenic (Von Kossa staining, 21 d), and adipogenic (Oil Red staining, 21 d) potential preserved | [97] | | CoCl2/100 μM | Pretreatment for 1-2 d | mC3H/10T1/2-MSC | Osteogenesis (Alizarin Red staining, 18 d) and expression of the Col I, Bglap, and Alp genes (RT-PCR, 10 d) enhanced, adipogenesis (Oil Red staining, 5 d) and expression of the Ap2, C/ebpα, and Pparγ genes (RT-PCR, 5 d) reduced, chondrogenesis (Alcian Blue staining, 14 d) and expression of SOX9, Col II, and ACAN genes (RT-PCR, 10 d) enhanced | [101] | | CoCl2/100 μM | Pretreatment for 2 d | hDP-MSC
hUC-MSC
hAD-MSC | Chondrogenesis (Alcian Blue, 28 d) in AD- and UC-MSC increased, in DP-MSC—not detected, cell-source dependent changes of the expression of the following genes: COL2A1, ACAN, SOX9, and VCAN (RT-PCR): DP-MSC–SOX9 (after 7 d up, and after 14, 21, and 28 d downregulated), VCAN (after 7, 14, 21, and 28 d upregulated), COL2A1 and ACAN not detected
UC-MSC–SOX9 (after 7, 28 d down, and after 14 and 21 d upregulated), COL2A1, ACAN, and VCAN (after 7,14, 21, and 28 d—upregulated)
AD-MSC–SOX9 (after 7 d up-, and after 14, 21, and 28 d downregulated), COL2A1 (after 7,14, 21, and 28 d upregulated), and ACAN upregulated only after 14 d, VCAN (after 7,14, 21, and 28 d downregulated) | [53] | | CoCl2/100 μM | Treatment for 8 d | mBM-MSC | Adipogenic potential preserved (Sudan Black staining, 8 d), Oct4 expression maintained (qRT-PCR) | [123] | | CoCl2/100 μM | Treatment for 9 d | Coculture
hBM-MSC
HUVEC | Osteogenic potential retained (Alizarin Red, nine days), expression of RUNX2, ALP, and COLIA1 maintained (qRT-PCR) | [52] | | CoCl2/100 μM | Treatment for 21 d | hUC-MSC | Osteogenic (Von Kossa staining, 21 d), and adipogenic (Oil Red staining, 21 d) potential preserved | [97] | | CoCl2/100 μM | Treatment for 21 d | hBM-MSC | Chondrogenesis (Alcian Blue, 21 d) and SOX9 expression (RT-PCR 7d) maintained | [124] | | DMOG/200 μM | Treatment for 21 d | hBM-MSC | Chondrogenesis (Alcian Blue, 21 d) and SOX9 and RUNX2 expression (RT-PCR, 7 d) increased | [124] | | DMOG/500 μM | Pretreatment for 2 d | rBM-MSC | Osteogenesis (Alizarin Red S, 21 d) and ALP activity (7 d) increased | [80] | | DMOG/500 μM +1%O2 | Pretreatment for 2 d | rBM-MSC | Osteogenesis (Alizarin Red S, 21 d) and ALP activity (7 d) increased | [80] | | DMOG/500 μM | Treatment for 9 d | Coculture
hBM-MSC
HUVEC | Osteogenic potential retained (Alizarin Red, 9 d), expression of RUNX2 maintained (qRT-PCR), expression of ALP and COLIA1 increased (qRT-PCR) | [52] |
|
|
